Market Overview

Seelos Therapeutics Shares Rally Following Deal For Gene Therapy Program


Seelos Therapeutics (NASDAQ: SEEL) shares traded higher after news emerged the company acquired the license of gene therapy program to address Parkinson's disease from Duke University.

The gene therapy program targets the regulation of the SNCA gene. Seelos plans to study this approach, named SLS-004, initially in Parkinson’s disease.

Seelos Therapeutics shares traded higher by 12.5% to $2.51 in Thursday's pre-market session.

Related Links:

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

Posted-In: Parkinson's DiseaseNews Health Care General


Related Articles (SEEL)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Credit Suisse Initiates Tesla At Underperform, Says Company Compares 'Most Appropriately' To Volkswagen

Benzinga's Top Upgrades, Downgrades For June 27, 2019